EUVIMEDEUVIMED entdecken
Open Access

Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota

Xiaolei Yang, Chenyang Zhu, Bei Liu, Ping Yang, Zhonglian Cao, Jingru Liang iD, Jiarong Hu, Qiuxia Yu, Yu Zhong, Wandi Du, Junwei Chow, Shiwei Yan und 5 weitere

Phytotherapy Research · 2026-08 · 40 (8) · 5016-5029

DOI: 10.1002/ptr.70205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 07.04.2026. Verfasst von Xiaolei Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, C…. Hauptthemen laut MEDLINE: Saponins, Triterpenes, Gastrointestinal Microbiome, Hypoglycemic Agents. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Astragaloside IV (AS‐IV), a main active ingredient derived from Astragali Radix , displays a favorable effect in treating type 2 diabetes mellitus (T2DM). This study was aimed to figure out its antidiabetic mechanisms. The db/db mice were treated with AS‐IV, and the metabolism phenotype and epithelial barrier permeability were tested. Trans‐epithelial resistance assay was performed in Caco‐2 cells. Metagenomic sequencing was used to determine the gut microbiota composition and function. The content of short‐chain fatty acid (SCFA) in feces was determined using Agilent 8890‐5977B GC–MS. Despite increasing mice body weight, AS‐IV significantly reduced hyperglycemia in the db/db mice, decreased the ratio of liver weight/body weight, alleviated hepatic total cholesterol and triglyceride levels. AS‐IV reduced inflammation through suppressing pro‐inflammatory genes ( Il1b, Tnf, Ccl2 ) and elevating anti‐inflammatory genes ( Il10, Il4, Il13, Il33 ) in the colonic epithelium. AS‐IV also reversed the increased intestinal permeability and decreased expression of tight junction (TJ) proteins Claudin‐1, ZO‐1 in the db/db mice and Claudin‐1, Occludin in Caco‐2 cells. Additionally, metagenomic sequencing showed AS‐IV altered composition and function of gut microbiota. The 80 species of gut microbiota were markedly changed, e.g., boosting of Alistipes spp. and Prevotella copri , decreasing of relative abundance of Ruminococcus gnavus and Enterocloster bolteae . AS‐IV upregulated the SCFA related pathway, increased the content of SCFA, upregulated the transcription levels of SCFA receptors (i.e., GPR41, GPR43 and GPR109a), thereby improved glucose metabolism in the db/db mice. These findings demonstrate that AS‐IV exhibited favorable antidiabetic effects by improving glucose metabolism and altering intestinal microbiota symbiosis via repairing the damaged gut barrier. This study will provide valuable reference for the development of new antidiabetic drugs and medication of T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SaponinsTriterpenesGastrointestinal MicrobiomeHypoglycemic AgentsGlucoseAnimalsHumansCaco-2 CellsMiceIntestinal Barrier FunctionMaleDiabetes Mellitus, Type 2Fatty Acids, VolatileMice, Inbred C57BLIntestinal MucosaFecesBlood Glucose

Stichwörter der Autor:innen

Astragaloside IVglucose metabolismgut microbiotaintestinal barriertype 2 diabetes mellitus

Substanzen

astragaloside ASaponinsTriterpenesHypoglycemic AgentsFatty Acids, VolatileGlucoseBlood Glucose

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, China.
  • Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Jingru Liang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, X., Zhu, C., Liu, B., Yang, P., Cao, Z., Liang, J., Hu, J., Yu, Q., Zhong, Y., Du, W., Chow, J., Yan, S., Liu, H., Li, L., Wang, T., Gu, Y., & Ma, G. (2026). Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota. Phytotherapy Research, 40(8), 5016-5029. https://doi.org/10.1002/ptr.70205

Vancouver

Yang X, Zhu C, Liu B, Yang P, Cao Z, Liang J, et al. Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota. Phytotherapy Research. 2026;40(8):5016-5029. doi:10.1002/ptr.70205

BibTeX
@article{Yang2026,
  author = {Yang, Xiaolei and Zhu, Chenyang and Liu, Bei and Yang, Ping and Cao, Zhonglian and Liang, Jingru and Hu, Jiarong and Yu, Qiuxia and Zhong, Yu and Du, Wandi and Chow, Junwei and Yan, Shiwei and Liu, Haiyang and Li, Longzhou and Wang, Tiandian and Gu, Yanyun and Ma, Guo},
  title = {Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {8},
  pages = {5016--5029},
  doi = {10.1002/ptr.70205}
}
Kostenlos starten →